Business
Two Parsortix posters presented at SABCS
Two Parsortix posters presented at SABCS.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n \n \n 12 December 2022\n \n \n \n \n \n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n \n \n TWO PARSORTIX POSTERS PRESENTED AT LEADING BREAST CANCER CONFERENCE\n \n \n \n \n \n \n \n \n \n Studies demonstrate the utility of the Parsortix PC1 Clinical System to isolate and harvest CTCs from metastatic breast cancer patients for further downstream analysis\n \n \n \n \n \n \n \n \n \n Harvested CTCs underwent cytological, immunofluorescent and molecular downstream evaluation\n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company,\n is pleased to announce the presentation of two posters at the San Antonio Breast Cancer Symposium (SABCS), in San Antonio, Texas, United States, between 06-10 December 2022. The studies demonstrated the successful isolation and subsequent analysis of circulating tumour cells (CTCs) from Metastatic Breast Cancer (MBC) patient blood samples using the Parsortix® PC1 Clinical System.\n \n \n \n \n \n The first poster, presented by ANGLE, outlines the utility of the Parsortix PC1 Clinical System in capturing and harvesting CTCs from a significantly larger proportion of MBC patients, compared to healthy donor samples. The ANG-008 study evaluated 75 MBC patient blood samples and 71 healthy volunteer blood samples. Firstly, the harvested CTCs were deposited onto glass slides for staining using cytocentrifugation, a method which has been shown to lose a significant proportion of cells. The cells retained on the cytology slides were stained using an immunofluorescence (IF) assay, and CTCs were characterized as nucleated cells that were positive for CK and/or EpCAM and negative for blood markers. The IF-stained slides were subsequently restained using Wright-Giemsa reagents and CTCs identified by a qualified pathologist. CTCs were observed in 45.3% and 42.9% of MBC patients following IF and Wright-Giemsa evaluation, respectively. Of the CTC-positive MBC patient samples, 70.6% had CK positive and EpCAM negative cells only. This high proportion of EpCAM negativity highlights the limitations of using EpCAM-based approaches to capture CTCs and the advantages of using the epitope-independent Parsortix PC1 Clinical System.\n \n \n \n \n \n The second poster, pre...